Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:IDXG

Interpace Biosciences (IDXG) Stock Price, News & Analysis

Interpace Biosciences logo

About Interpace Biosciences Stock (NASDAQ:IDXG)

Key Stats

Today's Range
$3.00
$3.46
50-Day Range
$4.75
$10.40
52-Week Range
$2.57
$10.42
Volume
20,385 shs
Average Volume
15,657 shs
Market Capitalization
$14.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDXG Stock News Headlines

PDI: Beware The Massive NAV Premium
Interpace Biosciences Inc.
Breaking News: Tesla headed to $500…
That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
Interpace Biosciences Reports Impressive Q3 2024 Growth
PDI: The Big ROC Bath, 13.5% 'Yield'
Healthcare Stocks Pre-Market Movers
See More Headlines

IDXG Stock Analysis - Frequently Asked Questions

Interpace Biosciences, Inc. (NASDAQ:IDXG) announced its earnings results on Wednesday, March, 29th. The business services provider reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.26. The business services provider earned $8.33 million during the quarter. Interpace Biosciences had a net margin of 10.39% and a negative trailing twelve-month return on equity of 8.09%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol-Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX).

Company Calendar

Last Earnings
3/29/2023
Today
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:IDXG
CUSIP
69329V10
Employees
152
Year Founded
N/A

Profitability

Net Income
$800,000.00
Pretax Margin
10.93%

Debt

Sales & Book Value

Annual Sales
$40.21 million
Cash Flow
$0.69 per share
Book Value
($13.11) per share

Miscellaneous

Free Float
4,157,000
Market Cap
$14.43 million
Optionable
Not Optionable
Beta
0.62
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:IDXG) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners